These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24275850)

  • 1. Glibenclamide for the treatment of acute CNS injury.
    Kurland DB; Tosun C; Pampori A; Karimy JK; Caffes NM; Gerzanich V; Simard JM
    Pharmaceuticals (Basel); 2013 Oct; 6(10):1287-303. PubMed ID: 24275850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylurea Receptor 1, Transient Receptor Potential Cation Channel Subfamily M Member 4, and KIR6.2:Role in Hemorrhagic Progression of Contusion.
    Gerzanich V; Stokum JA; Ivanova S; Woo SK; Tsymbalyuk O; Sharma A; Akkentli F; Imran Z; Aarabi B; Sahuquillo J; Simard JM
    J Neurotrauma; 2019 Apr; 36(7):1060-1079. PubMed ID: 30160201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glibenclamide for the treatment of ischemic and hemorrhagic stroke.
    Caffes N; Kurland DB; Gerzanich V; Simard JM
    Int J Mol Sci; 2015 Mar; 16(3):4973-84. PubMed ID: 25749474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date.
    King ZA; Sheth KN; Kimberly WT; Simard JM
    Drug Des Devel Ther; 2018; 12():2539-2552. PubMed ID: 30147301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUR1-TRPM4 channels, not K
    Woo SK; Tsymbalyuk N; Tsymbalyuk O; Ivanova S; Gerzanich V; Simard JM
    Neurosci Lett; 2020 Jan; 718():134729. PubMed ID: 31899311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence.
    Jha RM; Bell J; Citerio G; Hemphill JC; Kimberly WT; Narayan RK; Sahuquillo J; Sheth KN; Simard JM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain.
    Chen M; Dong Y; Simard JM
    J Neurosci; 2003 Sep; 23(24):8568-77. PubMed ID: 13679426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4.
    Simard JM; Kahle KT; Gerzanich V
    J Neurosurg; 2010 Sep; 113(3):622-9. PubMed ID: 20035575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice.
    Wang X; Chang Y; He Y; Lyu C; Li H; Zhu J; Liu K; Hu Y; Huang K; Pan S
    Neuropharmacology; 2020 Jan; 162():107845. PubMed ID: 31704276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On potential interactions between non-selective cation channel TRPM4 and sulfonylurea receptor SUR1.
    Sala-Rabanal M; Wang S; Nichols CG
    J Biol Chem; 2012 Mar; 287(12):8746-56. PubMed ID: 22291026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells.
    Mukai E; Ishida H; Kato S; Tsuura Y; Fujimoto S; Ishida-Takahashi A; Horie M; Tsuda K; Seino Y
    Am J Physiol; 1998 Jan; 274(1):E38-44. PubMed ID: 9458745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.
    Simard JM; Tsymbalyuk O; Keledjian K; Ivanov A; Ivanova S; Gerzanich V
    Exp Neurol; 2012 Jan; 233(1):566-74. PubMed ID: 22177998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers.
    Al-Karagholi MA; Ghanizada H; Nielsen CAW; Ansari A; Gram C; Younis S; Vestergaard MB; Larsson HB; Skovgaard LT; Amin FM; Ashina M
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1328-1337. PubMed ID: 33028147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury.
    Zweckberger K; Hackenberg K; Jung CS; Hertle DN; Kiening KL; Unterberg AW; Sakowitz OW
    Neuroscience; 2014 Jul; 272():199-206. PubMed ID: 24792709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP binding without hydrolysis switches sulfonylurea receptor 1 (SUR1) to outward-facing conformations that activate K
    Sikimic J; McMillen TS; Bleile C; Dastvan F; Quast U; Krippeit-Drews P; Drews G; Bryan J
    J Biol Chem; 2019 Mar; 294(10):3707-3719. PubMed ID: 30587573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T).
    Hambrock A; de Oliveira Franz CB; Hiller S; Osswald H
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1031-7. PubMed ID: 16306272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel.
    Woo SK; Kwon MS; Ivanov A; Gerzanich V; Simard JM
    J Biol Chem; 2013 Feb; 288(5):3655-67. PubMed ID: 23255597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Glibenclamide in Brain Injury After Intracerebral Hemorrhage.
    Jiang B; Li L; Chen Q; Tao Y; Yang L; Zhang B; Zhang JH; Feng H; Chen Z; Tang J; Zhu G
    Transl Stroke Res; 2017 Apr; 8(2):183-193. PubMed ID: 27807801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis.
    Gerzanich V; Makar TK; Guda PR; Kwon MS; Stokum JA; Woo SK; Ivanova S; Ivanov A; Mehta RI; Morris AB; Bryan J; Bever CT; Simard JM
    J Neuroinflammation; 2017 Sep; 14(1):177. PubMed ID: 28865458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.